Holders over time
- BIO
- JNJ
| Quarter | BIO | JNJ |
|---|---|---|
| Q3 2020 | 17 holders, $1.7bn | 30 holders, $26.2bn |
| Q4 2020 | 13 holders, $2.2bn | 32 holders, $26.6bn |
| Q1 2021 | 15 holders, $2.2bn | 31 holders, $25.3bn |
| Q2 2021 | 18 holders, $2.7bn | 37 holders, $25.6bn |
| Q3 2021 | 16 holders, $3.5bn | 40 holders, $24.1bn |
| Q4 2021 | 19 holders, $3.3bn | 33 holders, $25.2bn |
| Q1 2022 | 22 holders, $2.4bn | 35 holders, $28.2bn |
| Q2 2022 | 15 holders, $1.2bn | 33 holders, $26.9bn |
| Q3 2022 | 17 holders, $857m | 36 holders, $25.4bn |
| Q4 2022 | 16 holders, $782m | 35 holders, $27.6bn |
| Q1 2023 | 11 holders, $833m | 42 holders, $24.5bn |
| Q2 2023 | 16 holders, $607m | 38 holders, $25.0bn |
| Q3 2023 | 15 holders, $662m | 37 holders, $18.9bn |
| Q4 2023 | 11 holders, $534m | 31 holders, $19.0bn |
| Q1 2024 | 7 holders, $342m | 32 holders, $19.7bn |
| Q2 2024 | 6 holders, $409m | 35 holders, $20.4bn |
| Q3 2024 | 9 holders, $708m | 28 holders, $22.3bn |
| Q4 2024 | 11 holders, $649m | 37 holders, $20.4bn |
| Q1 2025 | 10 holders, $612m | 32 holders, $20.5bn |
| Q2 2025 | 8 holders, $780m | 31 holders, $18.4bn |
| Q3 2025 | 8 holders, $983m | 32 holders, $23.7bn |
| Q4 2025 | 9 holders, $1.2bn | 29 holders, $27.8bn |
| Q1 2026 | 8 holders, $1.2bn | 34 holders, $35.6bn |
| Q2 2026 | 7 holders, $1.1bn | 33 holders, $39.1bn |
Bio Rad Labs Inc
- Holders
- 7
- Reported value
- $1.1bn
- Buyers
- 15
- Sellers
- 13
Breadth +2 among 91 comparable managers.
Johnson & Johnson
- Holders
- 33
- Reported value
- $39.1bn
- Buyers
- 18
- Sellers
- 21
Breadth -3 among 91 comparable managers.
Who holds both, Q2 2026
Both (6)
Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Freestone Grove Partners LP, GAMCO Investors Inc
Only BIO (1)
Only JNJ (27)
Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Voloridge Investment Management LLC, and 2 more
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.